




Strategies Based on 2014 ASCCP Recommendations^a



Strategy Based on 2020 ACS Recommendations



Abbreviations	
ACS	American Cancer Society
ASC-US	Atypical squamous cells of undetermined significance
ASCCP	American Society for Colposcopy and Cervical Pathology
CIN2+	Cervical squamous intraepithelial neoplasia grade 2 or more severe disease
HPV	Human papillomavirus
hrHPV	High-risk HPV
LSIL	Low-grade squamous intraepithelial lesion
NAA	Nucleic acid amplification
NILM	Negative for intraepithelial lesion or malignancy

^aScreening is not recommended for individuals who are posthysterectomy with no history of cervical cancer or CIN2+.
^bClient should retain aliquot for cytology testing in case of hrHPV positivity.

References

The American Society for Colposcopy and Cervical Pathology. [Algorithms: updated consensus guidelines for managing abnormal cervical screening tests and cancer precursors](#). [Updated: Aug 2014; Accessed: Apr 2020]

Fontham ETH, Wolf AMD, Church TR, et al. [Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society](#). *CA Cancer J Clin*. 2020;70(5):321-346.

Huh WK, Ault KA, Chelmow D, et al. [Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance](#). *Gynecol Oncol*. 2015;136(2):178-182.

Massad S, Einstein MH, Huh WK, et al. [2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors](#). *Obstet Gynecol*. 2013;121(4):829-846.